Abstract
Clinical evidence suggests that antibodies from reconvalescent donors (persons who have recovered from infection) may be effective in the treatment of Ebola virus infection. Administration of this treatment to Ebola virus–infected patients while preventing the transmission of other pathogenic viruses may be best accomplished by use of virus-inactivated reconvalescent plasma.
Highlights
Clinical evidence suggests that antibodies from reconvalescent donors may be effective in the treatment of Ebola virus infection
Supported by scarce yet positive clinical evidence (1) and some recent animal model data (2), the use of whole blood or plasma transfusions from reconvalescent donors that contain antibodies to the Ebola virus has received substantial attention as a treatment alternative
The limitations of testing have been highlighted by transmission of West Nile virus (WNV) through blood transfusions in the United States even after implementation of sophisticated nucleic acid testing schemes for the blood supply (6)
Summary
Clinical evidence suggests that antibodies from reconvalescent donors (persons who have recovered from infection) may be effective in the treatment of Ebola virus infection. Supported by scarce yet positive clinical evidence (1) and some recent animal model data (2), the use of whole blood or plasma transfusions from reconvalescent donors (persons who have recovered from Ebola infection) that contain antibodies to the Ebola virus has received substantial ( media) attention as a treatment alternative.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
